Uguquko lwe-KRAS 8

Utshintsho lwezikhombisi kwi-gene ye-KRAS lufunyenwe kwiintlobo ezahlukeneyo ze-tumor ebantwini, malunga ne-17% ~ 25% yezinga lokuguquka kwi-tumor, i-15% ~ 30% yezinga lokuguquka kwizigulane ezinomhlaza wemiphunga, i-20% ~ 50% yezinga lokuguquka kwizigulane ezinomhlaza we-colorectal. Ngenxa yokuba iprotheni ye-P21 efakwe yi-gene ye-K-ras ifumaneka ngezantsi kwendlela yokubonisa i-EGFR, emva kotshintsho lwe-gene ye-K-ras, indlela yokubonisa esezantsi isoloko isebenza kwaye ayichaphazeleki ngamayeza ajoliswe phezulu kwi-EGFR, nto leyo ebangela ukwanda okuqhubekayo kweeseli ezinobungozi. Utshintsho kwi-gene ye-K-ras ludla ngokunika ukumelana ne-EGFR tyrosine kinase inhibitors kwizigulane ezinomhlaza wemiphunga kunye nokuxhathisa amayeza e-anti-EGFR antibody kwizigulane ezinomhlaza we-colorectal. Ngowama-2008, iNational Comprehensive Cancer Network (NCCN) yakhupha isikhokelo sonyango lomhlaza we-colorectal, esathi iindawo zokuguqula i-K-ras zisebenza ikakhulu zifumaneka kwi-codons 12 kunye ne-13 ye-exon 2, kwaye yacebisa ukuba zonke izigulana ezinomhlaza we-colorectal oqhubele phambili zinokuvavanywa utshintsho lwe-K-ras ngaphambi kokuba unyango luqale. Ke ngoko, ukufunyanwa ngokukhawuleza nangokuchanekileyo koguquko lwe-K-ras gene kubaluleke kakhulu kwisikhokelo samayeza eklinikhi. Le khithi isebenzisa i-DNA njengesampulu yokufumanisa ukubonelela ngovavanyo olusemgangathweni lwesimo soguquko, olunokunceda oogqirha ekuhloleni umhlaza we-colorectal, umhlaza wemiphunga kunye nezinye izigulana ezine-tumor ezixhamla kumayeza ajoliswe kuwo. Iziphumo zovavanyo lwekhithi zezereferensi yeklinikhi kuphela kwaye akufuneki zisetyenziswe njengesiseko sodwa sonyango oluzimeleyo lwezigulana. Oogqirha kufuneka benze izigqibo ezipheleleyo kwiziphumo zovavanyo ngokusekelwe kwizinto ezifana nemeko yesigulana, iimpawu zamayeza, impendulo yonyango kunye nezinye izalathisi zovavanyo lwelebhu.